Replies to post #54175 on Biotech Values

[ThomasS]

Ahhh, but ultimately, there will be fewer refractory patients to treat due to the improvement in treatment-naive.
I have not ever invested in VRTX, nor will I. I did have VRUS, briefly, at sub-$10.